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Budapest, HungaryBiologic drugs such as inﬂiximab and other anti–tumor
necrosis factor monoclonal antibodies have transformed
the treatment of immune-mediated inﬂammatory condi-
tions such as Crohn’s disease and ulcerative colitis (collec-
tively known as inﬂammatory bowel disease [IBD]).
However, the complex manufacturing processes involved in
producing these drugs mean their use in clinical practice is
expensive. Recent or impending expiration of patents for
several biologics has led to development of biosimilar ver-
sions of these drugs, with the aim of providing substantial
cost savings and increased accessibility to treatment. Bio-
similars undergo an expedited regulatory process. This in-
volves proving structural, functional, and biological
biosimilarity to the reference product (RP). It is also ex-
pected that clinical equivalency/comparability will be
demonstrated in a clinical trial in one (or more) sensitive
population. Once these requirements are fulﬁlled, extrapo-
lation of biosimilar approval to other indications for which
the RP is approved is permittedwithout the need for further
clinical trials, as long as this is scientiﬁcally justiﬁable.
However, such justiﬁcation requires that the mechanism(s)
of action of the RP in question should be similar across
indications and also comparable between the RP and the
biosimilar in the clinically tested population(s). Likewise,
the pharmacokinetics, immunogenicity, and safety of the RP
should be similar across indications and comparable be-
tween the RP and biosimilar in the clinically tested pop-
ulation(s). To date, most anti–tumor necrosis factor
biosimilars have been tested in trials recruiting patients
with rheumatoid arthritis. Concerns have been raised
regarding extrapolation of clinical data obtained in rheu-
matologic populations to IBD indications. In this review, we
discuss the issues surrounding indication extrapolation,
with a focus on extrapolation to IBD.Abbreviations used in this paper: ADA, anti-drug antibody; ADCC,
antibody-dependent cell cytotoxicity; AS, ankylosing spondylitis; CD,
Crohn’s disease; CRP, C-reactive protein; EMA, European Medicines
Agency; FDA, Food and Drug Administration; IBD, inﬂammatory bowel
disease; Ig, immunoglobulin; PK, pharmacokinetics; RA, rheumatoid
arthritis; RCT, randomized controlled trial; RP, reference product; sTNF,
soluble tumor necrosis factor; tmTNF, transmembrane tumor necrosis
factor; TNF, tumor necrosis factor; UC, ulcerative colitis.Keywords: Biosimilar; Extrapolation; Inﬂammatory Bowel
Disease; CT-P13; Inﬂiximab; Inﬂiximab-dyyb.
Crohn’s disease (CD) and ulcerative colitis (UC),collectively known as inﬂammatory bowel disease
(IBD), are chronic, relapsing immune-mediated inﬂam-
matory diseases of the gastrointestinal tract. The advent
of biologic drugs, starting with the anti–tumor necrosis
factor (TNF) monoclonal antibodies, has signiﬁcantly
improved outcomes for patients with IBD.
The relatively high cost of anti-TNF agents and their
looming or actual patent expiration have triggered the
development of highly similar versions of these drugs
that are known as biosimilars. Compared with origi-
nator biologics, biosimilars follow an expedited process
for regulatory approval. Most notably and provided
that certain requirements are met, virtually all regula-
tory agencies allow, in principle, for extrapolation of
indications. Extrapolation means that once bio-
similarity has been established in 1 or more in-
dications, a biosimilar may be approved for additional
or all other indications for which the originator, or
reference product (RP), has been approved without the
need for clinical trials in the latter indications.1,2
Nonetheless, there has been much debate on the val-
idity of extrapolation of clinical data for biosimilars.3–6
In this review, we consider the fears and facts
regarding extrapolation of biosimilar data to IBD,
starting with a brief introduction to some important
biosimilar concepts.Most current article
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The World Health Organization deﬁnes a biosimilar
as a “biotherapeutic product which is similar in terms
of quality, safety and efﬁcacy to an already licensed
reference biotherapeutic product”.7 The primary
amino acid sequences of a biosimilar and its RP are the
same, although often subtle variations in their complex
manufacturing processes mean the 2 products are not
identical in every way. In fact, the inherent variability
of the living bacteria-based systems used to make all
biologic drugs means no 2 batches of a single biologic
(either an RP or biosimilar) will ever be exactly alike.8
For RPs, batch-to-batch microheterogeneity, or
changes due to alterations in manufacturing processes,
are acceptable if the product falls within deﬁned
tolerance boundaries.9,10 This principle is similarly
applied to the development of biosimilars; minor dif-
ferences in clinically inactive components between the
biosimilar and RP are considered acceptable as long as
there are no clinically meaningful differences between
the drugs in terms of safety, purity, and potency.2
Comprehensive comparability testing is required to
prove biosimilarity and to show that any differences
found are not clinically meaningful. Such testing begins
with a detailed analytical comparison of a biosimilar and
its RP in terms of structure and functional/biologicalTable 1. Biosimilars Approved or Under Development for Possi
RP Biosimilar name Company
Inﬂiximab CT-P13 (Remsima®;
Inﬂectra®)
CELLTRION
SB2 (Flixabi®) Samsung Bioepis
BOW015
(Inﬁmab)
Epirus Biopharmaceuticals/Sun
Pharma/Ranbaxy Laboratories
NI-07121 Nichi-Iko Pharmaceutical
PF-06438179 Pﬁzer/Sandoz
Adalimumab ABP 501 Amgen
Exemptia Zydus Cadila
SB5 Samsung Bioepis
MSB1102281 Merck KGaA
GP2017 Sandoz
BI695501 Boehringer Ingelheim
FKB32782 Fujiﬁlm Kyowa Kirin Biologics
PF-06410293 Pﬁzer
CHS-1420 Coherus Biosciences
M923 Momenta Pharmaceuticals/Baxalta
LBAL83 LG Life Sciences/Mochida
Pharmaceutical
ONS-3010 Oncobiologics/Viropro
BOW050 Epirus Biopharmaceuticals
Golimumab BOW100 Epirus Biopharmaceuticals
Certolizumab
pegol
PF688 Pfenex
Xcimzane Xbrane
PsO, plaque psoriasis.
aInformation was obtained from company websites unless otherwise stated.activity, complemented with nonclinical in vivo studies.
However, the expedited process for biosimilar develop-
ment requires fewer clinical data than were needed for
its RP. According to guidance provided by the U. S. Food
and Drug Administration (FDA) and the European Med-
icines Agency (EMA), the clinical efﬁcacy and side effects
of a biosimilar are anticipated to be studied in one of the
RP-approved indications.1,2The Biosimilar Landscape in
Inﬂammatory Bowel Disease
Four anti-TNF drugs (inﬂiximab, adalimumab, certo-
lizumab pegol, and golimumab) and 2 anti-integrin
antibodies (natalizumab and vedolizumab) are pres-
ently approved in IBD indications in the United States.
Expiration of patents protecting some anti-TNF drugs
has heralded development of several biosimilars by
different companies (Table 1).
The inﬂiximab biosimilar CT-P13 (developed by
CELLTRION, Inc, Incheon, South Korea and marketed
under the trade name Remsima or Inﬂectra) was the
ﬁrst biosimilar licensed for use in IBD in Europe,
receiving approval from the EMA in September 2013. In
April 2016, CT-P13 was also approved in IBD by the
U. S. FDA with the generic name inﬂiximab-dyyb.11 Thisble Use in IBDa
Current development stage Approval status
Phase III completed in RA and AS Approved in Europe, USA,
and elsewhere
Phase III completed in RA Approved in Europe and Korea;
under review by FDA
Phase III trial in RA currently
recruiting
Approved in India only
Phase III completed in RA Not approved or under review
Phase III ongoing in RA Not approved or under review
Phase III completed in RA and PsO Approved in USA;
under review by EMA
Phase III completed in RA Approved in India only
Phase III completed in RA Under review by EMA
Phase III ongoing in PsO Not approved or under review
Phase III ongoing in PsO Not approved or under review
Phase III ongoing in RA Not approved or under review
Phase III ongoing in RA Not approved or under review
Phase III ongoing in RA Not approved or under review
Phase III ongoing in PsO Not approved or under review
Phase III ongoing in PsO Not approved or under review
Phase I completed in healthy
volunteers
Not approved or under review
Phase I completed in healthy
volunteers
Not approved or under review
Preclinical Not approved or under review
Preclinical Not approved or under review
Preclinical Not approved or under review
Preclinical Not approved or under review
December 2016 Biosimilars in IBD 1687approval meant that CT-P13 became the ﬁrst biosimilar
monoclonal antibody to be licensed in the United
States. Regulatory approval of CT-P13 was based on
comprehensive structural, functional, biological, and
other nonclinical comparisons with the inﬂiximab RP.
These analyses were supported by 2 randomized
controlled trials (RCTs) that demonstrated pharmaco-
kinetic (PK) and efﬁcacy equivalence, as well as
comparability of safety and immunogenicity, of CT-P13
and inﬂiximab RP in patients with active rheumatoid
arthritis (RA) or ankylosing spondylitis (AS).12–15
Extension studies of these RCTs also demonstrated
that treatment efﬁcacy, safety, and immunogenicity
were unaffected when patients were switched from RP
to CT-P13 at week 54 of treatment and followed up to
week 102.16,17 On the basis of all available data, CT-P13
was approved in RA and AS plus extrapolated in-
dications including CD and UC in regions/countries
including Europe, Japan, Australia, the United States,
and, most recently, Canada.11,18
Other inﬂiximab biosimilars, namely SB2, BOW015,
NI-071, and PF-06438179 (Table 1), have generally
followed similar developmental routes involving
comprehensive bioanalytical comparisons with the RP,
and some have completed phase III clinical trials.19–21
SB2 (developed by Samsung Bioepis, Incheon, South
Korea) is the only other inﬂiximab biosimilar to be
approved in Europe.22 None are yet approved in the
United States.
Patents protecting adalimumab are due to expire in
2016 and 2018 in the United States and Europe,
respectively. As a result, biosimilars for adalimumab are
potentially nearing launch (Table 1). The ﬁrst of these
may be ABP 501 (Amgen, Thousand Oaks, CA), which has
recently been approved by the US FDA, and is under
review by the EMA. Findings supporting the approval of
ABP 501 include PK equivalence versus adalimumab RP
in a phase I study in healthy subjects23 and equivalent
efﬁcacy and comparable safety and immunogenicity in
RCTs in RA and psoriasis.24,25 However, the United States
Patent and Trademark Ofﬁce has approved several pat-
ents that protect post-launch innovations regarding the
RP, including formulation and dosing schemes. Poten-
tially these new patents could effectively extend the life
of the whole adalimumab patent for another decade or
later. Thus, patent litigation will likely become an
important factor inﬂuencing market entry for adalimu-
mab biosimilars. Regarding other anti-TNF RPs, golimu-
mab and certolizumab patents will expire around the end
of this decade, and biosimilars of these drugs are also in
development (Table 1).
For the majority of biosimilars tested in clinical trials,
efﬁcacy versus each RP has been assessed in patients
with RA (Table 1). This choice was made and deemed
appropriate by regulatory agencies because clinical
experience with these drugs is greatest in RA, and
because RA is considered a sufﬁciently sensitive model
for establishing the equivalence of efﬁcacy between ananti-TNF biosimilar and its RP.26 Although most anti-TNF
biosimilar developers chose RA as the population for
efﬁcacy testing, some have also performed an additional
RCT in AS (as for CT-P13) or in psoriasis (as for ABP
501) (Table 1).Extrapolation: Why Is It Allowed and
When Is It Valid?
The guiding principle underpinning the development
of biosimilars is the hope of healthcare providers and
patients alike that these agents will reduce the ﬁnancial
costs of biologic therapy, thereby increasing access to
these drugs and facilitating intensiﬁed treatment regi-
mens when clinically required. For these beneﬁts to be
realized, extrapolation is necessary. This is because this
process reduces the number of clinical trials required for
biosimilar approval and thereby lowers development
costs. Nonetheless, extrapolation has also created con-
cerns regarding whether bioanalytical similarity coupled
with proven clinical safety and efﬁcacy in 1 or 2
indications can ensure safety and efﬁcacy in other
indications. However, although many unknowns exist
during development of an RP biologic, biosimilars enjoy
the conceptual advantage of having a known comparator
drug with well-deﬁned structure, biological function, and
clinical safety and efﬁcacy. On the other hand, each
“current” batch of an RP enjoys the putative advantage of
having been compared with the original batches used in
RP clinical trials. Original batches of an RP are not usu-
ally available to the biosimilar manufacturers, raising the
possibility of further “manufacturing drift” during the
biosimilars’ development.
For extrapolation to be considered valid by the FDA,
the mechanism of action, PK (including biodistribution),
immunogenicity, and safety of an RP all need to be
similar in the extrapolated indication(s) and the clinically
tested indication(s).2 If one of these attributes is unique
for an extrapolated indication, additional evidence is
required to show why the biosimilar can be anticipated
to behave similarly in that indication despite not being
tested clinically. Furthermore, if minor differences in
structure or function exist between the biosimilar and RP
and have negligible impact in clinical trials in the tested
indication, it should be shown why these differences
would also have negligible clinical meaning in the
extrapolated indication.
The validity of using extrapolation from clinical
trials in rheumatologic diseases to approve a biosimilar
in IBD can be tested by considering the following
questions:
 Are the mechanisms of action, PK, pharmacody-
namics, immunogenicity, and safety of the RP similar
between IBD and the clinically tested population,
and are they comparable between the RP and bio-
similar in that population?
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marketing surveillance programs and other “real-
life” data in IBD provide any reasons for concern?
In the following sections, we consider these questions
by referring to information on biosimilars approved or in
development for IBD.Comparing Mechanisms of Action
Across Indications
All indications for inﬂiximab and other anti-TNF
drugs are immune-mediated inﬂammatory diseases that
share common underlying pathophysiological processes,
with the proinﬂammatory cytokine TNF playing an
especially pivotal role.27 TNF can be expressed on the
cell surface as transmembrane TNF (tmTNF) or cleaved
and released as soluble TNF (sTNF). Binding of TNF to its
receptor triggers numerous intracellular forward-
signaling pathways, including induction of apoptosis in
some cell lineages (eg, intestinal epithelial cells) or
cellular activation and secretion of other proin-
ﬂammatory cytokines in others (eg, effector T cells).27
Anti-TNF monoclonal antibodies have large complex
structures comprising Fc and Fab regions, each medi-
ating different immune functions via diverse mechanisms
of actions. The binding and neutralization of TNF (both
sTNF and tmTNF) is a mechanism common to all anti-
TNF monoclonal antibodies (Figure 1). However, there
are other possible mechanisms of action of these drugs
that are also potentially instrumental in IBD.Figure 1. Established and possible mechanisms of action of inﬂi
Binding to tmTNF and sTNF neutralizes the biological effects of T
IBD. Binding to tmTNF also causes reverse signaling and induc
thought to possibly play a role in the control of IBD. ADCC and
of action of anti-TNF antibodies. CDC, complement-dependentReverse signaling. The binding of an anti-TNF anti-
body to tmTNF can trigger signaling pathways within
the tmTNF-expressing cell. This process is referred to
as reverse signaling, and its downstream effects include
induction of apoptosis and suppression of proin-
ﬂammatory cytokine expression, both of which are
believed to be important mechanisms of action for anti-
TNF agents in IBD.28,29 This contention is supported by
the fact that reverse signaling is induced by TNF in-
hibitors that are clinically effective in IBD, including
inﬂiximab and adalimumab, but not by etanercept
(which primarily blocks sTNF and is ineffective in
IBD).30,31 As such, although the etanercept biosimilar
SB4 was recently approved by the EMA, this drug (like
its RP) is not licensed in IBD.32 Both blockade of
proinﬂammatory cytokines and induction of apoptosis
via reverse signaling were shown to be highly compa-
rable for CT-P13 and for ABP 501 versus their
respective inﬂiximab and adalimumab RPs
(Table 2),26,33,34 serving as part of the scientiﬁc justi-
ﬁcation for their extrapolation to IBD. Functional data
on other anti-TNF biosimilars are not currently
available.
Induction of regulatory macrophages. Regulatory (M2)
macrophages can reduce T cell proliferation.35 In an in-
testinal cell-line model, inﬂiximab and adalimumab RPs
were shown to induce regulatory macrophages in an Fc-
dependent mechanism to mediate wound healing,35,36
possibly explaining their mucosal healing capacity. In
contrast, certolizumab (which lacks the Fc region) does
not induce regulatory macrophages.35 This fact mayximab and some other anti-TNF monoclonal antibodies in IBD.
NF, preventing ampliﬁcation of inﬂammation that can occur in
tion of apoptosis and regulatory M2 macrophages, which are
CDC have been suggested but not shown to be a mechanism
cytotoxicity; MOA, mechanism of action; NK, natural killer.
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States, certolizumab was associated with a low rate (4%)
of complete mucosal healing in one clinical study.37 It
may also partly explain why an anti-TNF immunoglob-
ulin (Ig) G1 construct with reduced Fc binding did not
ameliorate murine colitis.38 For biosimilars, data on this
possible anti-TNF mechanism of action in IBD are rela-
tively scant, although comparable induction of regulatory
macrophages and wound healing in an intestinal cell
model was observed for CT-P13 and inﬂiximab RP
(Table 2).Table 2. Available Published Evidence on Comparable Function
Respective RPs
Functional/
biological activity CT-P13 vs inﬂiximab RP34
Binding to TNF  Comparable binding to hTNF as determined by
 Comparable binding to monomeric and trimeric
determined by surface plasmon resonance
 Comparable binding to tmTNF as determined by
ELISA
Neutralization  Comparable and dose-dependent neutralization
assay by using a TNF-sensitive cell line
 Comparable and dose-dependent suppression o
secretion by blocking sTNF in an IBD model (ep
 Comparable and dose-dependent suppression o
blocking sTNF in an IBD model (epithelial cells)
Binding to Fcg
receptors
 Comparable relative binding afﬁnities to FcgRI,
and FcRn
 Reduced relative binding afﬁnities to FcgRIIIa an
CT-P13
 Reduced relative binding afﬁnities to NK cells of
donors and CD patients for CT-P13 (difference
genotype-speciﬁc [V/V and V/F] and disappeare
of diluted CD patient serum)
 Comparable binding afﬁnities to neutrophils from
or CD patients
Reverse signaling  Comparable induction of apoptosis by reverse s
tmTNF by using a cell-based assay (PBMC from
and CD patients)
 Comparable blockade of proinﬂammatory cytok
reverse signaling by using a cell-based assay (PB
donors and CD patients)
Cytotoxicity  Comparable C1q binding and CDC activity as d
ELISA and other assays
 Comparable ADCC activity by using tmTNF-exp
cells as target cells and PBMC or NK cells from
as effector cells
 Comparable ADCC activity by using tmTNF-exp
cells as target cells and PBMC from CD patient
 Reduced ADCC activity for CT-P13 by using tm
Jurkat cells as target cells and NK from CD pati
cells (genotype-speciﬁc)
 Comparable ADCC activity by using tmTNF-exp
cells as target cells and whole blood from health
patients as effector cells
 Comparable ADCC activity by using LPS-stimul
from healthy donors or CD patients as target ce
as effector cells
NOTE. Data on other biosimilars in development were not in the public domain a
CDC, complement-dependent cytotoxicity; ELISA, enzyme-linked immunosorben
peripheral blood mononuclear cells.Antibody-dependent cell cytotoxicity. Antibody-
dependent cell cytotoxicity (ADCC) is primarily mediated
by antibodies that ﬁrst coat a target cell. These antibodies
then interact via their Fc regionwith the FcgRIIIa receptor
on natural killer cells (and some macrophages) to induce
lysis of the target cell.39 There is still debate as to whether
ADCC plays a role in mediating the effects of anti-TNF
drugs in IBD. Supporting evidence includes the fact that
etanercept is incapable of ADCC induction and is ineffec-
tive in IBD, although this could also be explained by the
inability of etanercept to induce apoptosis via reverseal/Biological Activity of CT-P13 and ABP 501 and Their
ABP 501 vs adalimumab RP33
ELISA
hTNF as
a cell-based
 Comparable binding afﬁnity to sTNF as
determined by surface plasmon resonance
 Comparable binding to tmTNF as determined
by competitive imaging cytometry-based assay
in a cell-based
f cytokine
ithelial cells)
f apoptosis by
 Comparable blocking of TNF-induced caspase
activation
 Comparable blocking of TNF-induced
interleukin-8 secretion
 Comparable blocking of TNF-induced
cytotoxicity
FcgRIIa, FcgRIIb,
d FcgRIIIb for
healthy
was
d in presence
healthy donors
 Comparable binding to FcRn as determined in
a competitive cell-based assay
 Comparable binding to FcgRIIIa (158V) as
determined by AlphaLISA
ignaling through
healthy donors
ine production by
MC from healthy
 Not reported
etermined by
ressing Jurkat
healthy donors
ressing Jurkat
s as effector cells
TNF-expressing
ents as effector
ressing Jurkat
y donors or CD
 Comparable dose-response proﬁle for CDC by
using cells expressing tmTNF
 Comparable dose-response proﬁle for ADCC
by using cells expressing tmTNF
 Comparable dose-response proﬁle for ADCC
by using NK92-M1 cells expressing FcgRIIIa
(158V)
ated monocytes
lls and PBMC
t the time that this article was developed.
t assay; hTNF, human TNF; LPS, lipopolysaccharide; NK, natural killer; PBMC,
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an FF polymorphism variant of FcgRIIIa (which leads to
reduced IgG binding and diminished ADCC) exhibit a
diminished C-reactive protein (CRP) response to inﬂix-
imab, thereby indirectly implicating ADCC in mediating
inﬂiximab efﬁcacy.40,41 However, none of these studies
were able to show a correlation between FcgRIIIa and a
clinical response to inﬂiximab. Furthermore, a larger
analysis based on the ACCENT I trial population did not
ﬁnd a statistically signiﬁcant CRP-response correlation
with speciﬁc polymorphisms.42 Moreover, in 2 studies the
VV genotype was associated with higher baseline CRP
levels.41,43 This suggests that FcgRIIIa polymorphisms
may actually indicate a CDpopulationwith higher baseline
inﬂammation, confounding any observations of an
apparent reduction in CRP response. Indeed, the evidence
against ADCC having a role in anti-TNF efﬁcacy in IBD is
also considerable and perhaps more compelling. First,
experiments demonstrating ADCC by inﬂiximab exclu-
sively use target cells artiﬁcially engineered to over-
express tmTNF, whereas studies that use more
physiological target cells (eg, lipopolysaccharide-
triggered monocytes, activated T cells) show no ADCC
with inﬂiximab.31,41 In addition, antibodies exerting ADCC
in vivo, such as anti-CD20 rituximab or anti-CD3 visilizu-
mab, are associated with cytokine release syndrome, an
adverse event attributed in part to rapid ADCC-mediated
cell death and consequent cytokine release.44–46 In
contrast, no such “cytokine storm” has been reported after
inﬂiximab administration in IBD. Interestingly, the entire
debate about ADCC was stirred by the fact that because of
a lower level of afucosylation, the binding afﬁnity of CT-
P13 to FcgRIIIa was reduced by around 10%–20%
versus inﬂiximab RP, resulting in lower ADCC activity to-
ward cell lines engineered to express artiﬁcially high
levels of tmTNF.26,34,47 However, there was no difference
in ADCC between CT-P13 and its RP when
lipopolysaccharide-triggered monocytes or intestinal
lamina propria cells were used as target cells, or when
assays were performed in the presence of serum (ie, more
physiologically relevant models for possible ADCC in
IBD).26 Overall, therefore, it seems that ADCC is unlikely to
be a major mechanism of action of inﬂiximab in IBD and
that any differences in ADCC between CT-P13 and inﬂix-
imab RP are not clinically relevant. These concepts were
upheld by the EMA and the FDA when considering the
approval of CT-P13 in IBD.
Pharmacokinetics Comparisons
PK equivalence of CT-P13 and inﬂiximab RP has been
demonstrated in 2 populations, AS and RA patients.12,48
An additional PK trial in healthy individuals was there-
after conducted to bridge between the European
Union–approved and US-approved formulations of
inﬂiximab RP and showed their comparable PK equiva-
lence with CT-P13.49 Equivalence of PK has also been
shown for BOW015 and inﬂiximab RP and foradalimumab RP and its biosimilars ABP 501 and
BI695501, all in healthy subjects.23,50,51
Systemic clearance of inﬂiximab seems to be some-
what higher in IBD than in rheumatologic indications.52–54
Although direct comparisons are lacking, studies have
indicated that albumin level is associatedwith clearance of
inﬂiximab in CD and UC but not in AS.52,53 Onemechanism
that may cause reduced serum albumin as well as has-
tened anti-TNF clearance in IBD is fecal loss of drug. Fecal
loss of inﬂiximab has been documented in severe UC and is
thought to be due to passive drug leakage to the gut lumen
and the shedding of epithelial cells into the lumen, effects
occurring as a consequence of severe diarrhea and
protein-losing enteropathy.55,56 The identical IgG back-
bone of an anti-TNF biologic and its biosimilar is likely to
result in comparable fecal loss of these drugs via these
passive mechanisms. A second mechanism of altered
clearance in IBD relates to the high tissue concentration of
TNF, which binds anti-TNF drugs and hastens clearance of
the TNF–drug complexes in a process known as target-
mediated drug disposition.55–57 However, comparable
TNF binding by an anti-TNF RP and its biosimilar, as
shown for CT-P13 and other biosimilars, means the effects
of high TNF-tissue burden will likely be similar.
Immunogenicity Comparisons
The immunogenicity of a biosimilar and its RP should
be fully characterized before extrapolation to other
indications because the generation of anti-drug anti-
bodies (ADAs) can impact on efﬁcacy and safety.58 No
difference in the proportion of ADA-positive patients was
observed between CT-P13 and RP in RA and AS
patients12–15 or in such patients who switched to CT-P13
from RP.16,17 Comparable immunogenicity between the
biosimilar and its RP was also observed in phase III trials
in RA involving the inﬂiximab biosimilar BOW01520 and
the adalimumab biosimilar ABP 501.25
Questions have arisen as towhether it is appropriate to
extrapolate immunogenicity data from RA and/or AS to
IBD. Of note, RA patients mostly receive inﬂiximab at
doses of 3 mg/kg and are often co-administered the
immunosuppressant methotrexate. In patients with IBD,
however, thiopurines are more often used in combination
with inﬂiximab, and methotrexate is seldom used in this
population. The comparability of immunogenicity sup-
pression by methotrexate and thiopurines is unknown.
Comparing immunogenicity between studies and patient
populations is therefore hampered by the use of different
concomitant immunomodulators but also by differences
in drug doses, sampling time-points, and ADA analysis
techniques.59 However, in 2 studies (COMMIT in CD and
ATTRACT in RA), overlapping doses of inﬂiximab plus
methotrexate and similar sampling time-points were
used.60,61 Although caution should be exercised in
interpreting immunogenicity rates in the absence of head-
to-head trials, comparable ADA development was
demonstrated in CD and RA patients in these 2 trials
December 2016 Biosimilars in IBD 1691(4% versus 8.5%, respectively). This suggests a broadly
similar immunogenicity proﬁle in the 2 diseases when
compared by using 2 similar methodology trials. Sup-
porting this contention, a cross-reactivity study showed
that ADAs against inﬂiximab RP in IBD patients similarly
recognize CT-P13, suggesting shared immune-dominant
epitopes between these 2 molecules in IBD populations.62
Safety Comparisons and Risks Unique to
Inﬂammatory Bowel Disease
Similar safety proﬁles for CT-P13 and inﬂiximab RP
were observed in AS and RA patients.12–15 Comparable
safety was also demonstrated for SB2 and inﬂiximab in
RA patients19 and during a phase III RA trial of BOW015
versus inﬂiximab RP.20 In addition, ABP 501 is reported
to have shown similar safety to adalimumab in both RA
and psoriasis populations.24,25
In IBD, inﬂiximab and other immunosuppressive
agents have been associated with exacerbation of
abdominal/perianal sepsis in ﬁstulizing CD, although
this risk can be negated if combined with appropriate
surgical care.63,64 In general, the risk of serious infec-
tion is increased with immunosuppression.65 As such,
all immunosuppressive agents are contraindicated in
patients with active untreated infections.65 Initial con-
cerns regarding the development of intestinal stricture
and bowel obstruction in CD patients treated with
inﬂiximab were not corroborated in a larger analysis of
the ACCENT I trial and TREAT registry.66 Similarly, no
stricture progression was observed in an ultrasound
study involving 15 CD patients who had strictures of
the small intestine before starting inﬂiximab.67 Thus,
stricture formation is unlikely to be a particular risk for
CD patients treated with inﬂiximab RP or its
biosimilars.
Collecting Real-life Data After Approval
Once a drug is approved, observational “real-world”
data can provide useful insights into its efﬁcacy as well
as important information regarding safety. These data
should be collected in safety registries as part of formal
post-marketing surveillance for RPs and biosimilars
alike. Currently, CT-P13 is the only biosimilar for which
real-world data in IBD are available. To date, most
studies have found CT-P13 to be efﬁcacious and well-
tolerated in IBD (Table 3).68–75
A nationwide prospective and observational cohort
study in Hungary examined the efﬁcacy, safety, and
immunogenicity of induction treatment with CT-P13 in
210 consecutively recruited patients with CD or UC.69 At
week 14, 81.4% and 77.6% of CD and UC patients,
respectively, had a clinical response, and 53.6% and
58.6%, respectively, were in remission. Response and
remission rates were maintained at week 30. Patients
who had previously been exposed to inﬂiximab RP hadsigniﬁcantly higher baseline ADA positivity compared
with inﬂiximab-naïve patients and demonstrated lower
early response and remission rates. Adverse events were
reported in 17.1% of all patients. Infusion reactions
occurred in 6.6% of patients and were signiﬁcantly more
common in those with previous inﬂiximab exposure.
Infectious adverse events were observed in 5.7% of
patients, resulting in 1 death.69 One study published as a
congress abstract reported higher rates of surgery and
other indicators of disease control in patients treated
with CT-P13 compared with those treated with inﬂix-
imab RP.76 However, rates of response and remission
were not reported, and there were some differences in
baseline characteristics between the 2 cohorts.
The effects of switching to CT-P13 from inﬂiximab RP
were investigated in a Polish study of 32 children with
CD and 7 with UC.75 In the CD subgroup, 22 patients
(69%) were in clinical remission before switching; the
other 10 had active mild/moderate disease. At the time
of the last assessment (mean follow-up after switch, 8
months; range, 2–11), 28 CD patients (87.5%) were in
clinical remission, suggesting maintained clinical effects
after switching. Remission was also observed in some UC
patients, although this subgroup was too small for reli-
able efﬁcacy comparisons. In general, adverse event
incidence did not differ signiﬁcantly before and after the
switch from inﬂiximab RP to CT-P13.
Biosimilars and Interchangeability
According to the US FDA, an interchangeable biological
product refers to a biosimilar that “meets additional stan-
dards for interchangeability” and “may be substituted for
the reference product by a pharmacist without the inter-
vention of the health care provider”.77 Currently, no bio-
similar manufacturers have applied for regulatory
approval for interchangeable status. As such, interchange-
ability cannot be supported for any biosimilar at this stage.
The issue of interchangeability should be distinguished
from a physician’s decision to switch between an RP and
biosimilar, or vice versa, which is designated as transition.
Single transitions from RP to biosimilar during mainte-
nance therapy have been tested in clinical trials of CT-
P1316,17 and also reported in real-world cohorts.75 No
apparent new safety or immunogenicity signals or changes
in efﬁcacy seemed to arise after such single transitions.
This is unlike multiple repeated transitions between an RP
and its biosimilar/s, which should be discouraged because
of absence of data on its safety and because of signiﬁcant
challenges to agent-speciﬁc surveillance when multiple
transitions are performed.
Opportunities Offered by Reduced
Cost of Biosimilars
The reduced price of biosimilars can lead to cost ef-
ﬁciencies and drive competition. In turn, this may beneﬁt
Table 3. Summary of Real-world Efﬁcacy and Safety of CT-P13 in IBDs
Study Follow-up IBD N TNF-naïve (n)
Efﬁcacy Safety
Clinical response (% of
patients; [n/N])
Remission rate (% of
patients; [n/N])
Adverse event (% of
patients; [n/N])
IRR (% of patients;
[n/N])
Farkas et al68 8 wk CD 18 16 37.5a (6/16) 50.0a (8/16) NR NR
UC 21 19 20.0a (3/15) 66.7a (10/15) NR NR
Gecse et al69 14 wk CD 126 93 81.4 (79/97) 53.6 (52/97) 17.1b (36/210) 6.6b (14/210)
UC 84 68 77.6 (45/58) 58.6 (34/58)
Jahnsen et al70 14 wk CD 46 33 NR 79.0 (34/43) NR 2.2 (1/46)
UC 32 27 NR 56.0 (18/32) NR 3.1 (1/32)
Jung et al71 54 wk CD 59 32 87.5c (7/8) 75.0c (6/8) 0.0 (0/59) 0.0
UC 51 42 100.0c (12/12) 50.0c (6/12) 11.8 (6/51) NR
Kang et al72 8 wk CD 8 3 66.7c (2/3) 66.7c (2/3) 0.0 NR
UC 9 5 100.0c (5/5) 100.0c (5/5) 0.0 NR
Keil et al73 14 wk CD 30 30 100.0 (30/30) 50.0 (15/30) NR 1.9 (1/52)
UC 22 22 95.5 (21/22) 40.9 (9/22)
Park et al74 30 wk CDd 95 51 77.8c (35/45) 57.8c (26/45) 17.9 (17/95) 2.1 (2/95)
UC 78 62 72.2c (39/54) 37.0c (20/54) 26.9 (21/78) 1.3 (1/78)
Sieczkowska et al75 8 mo (mean) pCD 32e 26 NR 87.5 (28/32) NR 3.1 (1/32)
5 mo (mean) pUC 7e 6 NR 57.1 (4/7) NR 28.6 (2/7)
NOTE. Data are from studies published in full form and listed on PubMed.
IRR, infusion-related reaction; NR, not reported; p, pediatric.
aOf patients who completed induction treatment.
bAt week 30.
cIn TNF-naïve patients only.
dIncluding ﬁstulizing active CD (n ¼ 12).
ePatients had switched from inﬂiximab to CT-P13.
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December 2016 Biosimilars in IBD 1693healthcare systems and improve patient care by
increasing access to biologic therapy and to intensiﬁed
dosing when indicated. In addition, increased afford-
ability and competition may allow more clinical trials in
certain clinical scenarios that are presently missing. For
example, some patients treated with inﬂiximab eliminate
the drug faster than others. Further research and appli-
cation of therapeutic drug monitoring for both RPs and
biosimilars could address such issues and facilitate
personalized dosing, with expected improved outcomes
and additional cost savings.78Conclusions
There is continued scientiﬁc debate on extrapolation
to IBD of anti-TNF biosimilars that are clinically tested in
RA populations, with concerns voiced by some experts as
well as some national professional societies.3–6 In
agreement with regulatory agencies around the world, it
appears that extrapolation can be a valid, evidence-based
approach for the expedited development of these new,
more accessible drugs. However, for this approach to be
valid, comprehensive analyses and well-thought justiﬁ-
cations should be provided, and extrapolation should be
considered on a case-by-case basis. This requires in-
depth understanding of a drug’s mechanisms of actions
in IBD and careful evaluation of differences in PK,
immunogenicity, and safety in IBD versus other in-
dications. For IgG monoclonal anti-TNF agents, it seems
that the major determinants of these attributes are
highly similar between IBD and other immune-mediated
inﬂammatory diseases, thereby justifying extrapolation
under the conditions outlined above. For CT-P13, the
only anti-TNF biosimilar currently approved in IBD, real-
world efﬁcacy and safety data appear to support
extrapolation to CD and UC indications, but more data
are pertinent, including those from ongoing phase III
RCTs in IBD.79,80References
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